BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:From computational pharmacy to modern drug discovery
DTSTART:20220906T163000
DTSTAMP:20260916T042536Z
UID:ebb8b9a24280e398ab22e5a2c99cf4445392eefa69da962db0b295a3
CATEGORIES:Conferences - Seminars
DESCRIPTION:Prof. Shuguang Yuan \nAbstract: Modern drug discovery is a lo
 ng and tedious process which costs at least 10 years and 2 billion USD in 
 average. How to speed up this expensive process has become one of the most
  essential topics in pharmaceutical industry. With the progresses in both 
 artificial intelligence and computational biology\, advancing modern drug 
 discovery via computational pharmacy plays more and more important roles. 
 In this talk\, Prof. Yuan will illustrate applying computational biology a
 nd artificial intelligence to answer fundamental questions in life science
 \, especially in the area of G protein-coupled receptors (GPCRs). He will 
 also discuss how to speed up modern drug discovery in an ultimate efficien
 t way. Finally\, Prof. Yuan will also talk about his successfully story on
  how to develop “first-in-class” drug molecules into clinical trials.\
 n\nSpeaker: Prof. Shuguang Yuan. He obtained his master degree in biochem
 istry and structural biology from the Shanghai Institute of Organic Chemis
 try (SIOC)\, Chinese Academy of Sciences in 2009. Following that\, his doc
 toral dissertation was funded by the Maria Curia Fellowship. It was conduc
 ted in three different institutes in Europe: EPFL(Switzerland)\, Polish Ac
 ademy of Science (Poland) and KULeuven University (Belgium). In his resear
 ch\, he investigated the principles of various biological systems includin
 g enzymes\, kinases\, ion channels\, transporters\, and in particular\, G
  protein-coupled receptors (GPCRs). In June 2013\, he was awarded with a P
 hD title with the honor of distinguished thesis. Following that\, he was o
 ffered the Marie Curie ETH Postdoc Fellowship. In 2014\, Dr. Yuan proposed
  a theory about the activation mechanism and the continuous water channel 
 of GPCRs (Nature Communications\, 2014)\, which has been widely recognized
  in this area. Prof. Yuan worked at Idorsia (previously known as Actelion)
  Pharmaceutical Ltd in Basel as a specialist in computer-aided drug design
  (CADD) for 5 years. In the past few years\, he has advanced two of his de
 signed molecules into clinical trials. In 2018\, he was honored with the t
 itle of "affiliate professor" by the University of Warsaw. In 2019\, Prof.
  Yuan was offered a full professor position by the Shenzhen Institute of A
 dvanced Technology\, CAS. He is also the director of the "Research Center 
 for Computer-aided Drug Discovery" (http://www.cadd2drug.org). In 2020\, P
 rof. Yuan established the start-up “AlphaMol Science Ltd” with Prof. H
 orst Vogel together in both Switzerland and China. AlphaMol combines innov
 ative computational methods with newly invented biotechnology to advance m
 odern drug discovery. Currently\, there are several “first-in-class” d
 rug discovery pipelines that are actively being progressed in AlphaMol.\n\
 n 
LOCATION:SV 1717 https://plan.epfl.ch/?room==SV%201717
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR